Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HOWL NASDAQ:LPCN NYSEAMERICAN:MTNB NASDAQ:MYNZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHOWLWerewolf Therapeutics$0.35$0.59$0.34▼$2.38$17.07M0.29619,821 shs1.58 million shsLPCNLipocine$2.33$2.29$1.81▼$12.37$19.21M0.48111,344 shs122,356 shsMTNBMatinas Biopharma$0.60$0.66$0.48▼$3.09$3.87M1.6770,017 shs58,934 shsMYNZMainz Biomed$1.76-7.4%$1.58$0.55▼$4.43$15.95M0.31371,589 shs1.79 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHOWLWerewolf Therapeutics+2.12%-10.88%-18.00%-55.31%-71.67%LPCNLipocine-0.43%+6.88%+5.91%-67.41%-27.19%MTNBMatinas Biopharma-14.93%-25.56%+8.44%-5.63%-32.88%MYNZMainz Biomed-2.06%-1.04%-42.42%+125.09%+24.18%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHOWLWerewolf Therapeutics$0.35$0.59$0.34▼$2.38$17.07M0.29619,821 shs1.58 million shsLPCNLipocine$2.33$2.29$1.81▼$12.37$19.21M0.48111,344 shs122,356 shsMTNBMatinas Biopharma$0.60$0.66$0.48▼$3.09$3.87M1.6770,017 shs58,934 shsMYNZMainz Biomed$1.76-7.4%$1.58$0.55▼$4.43$15.95M0.31371,589 shs1.79 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHOWLWerewolf Therapeutics+2.12%-10.88%-18.00%-55.31%-71.67%LPCNLipocine-0.43%+6.88%+5.91%-67.41%-27.19%MTNBMatinas Biopharma-14.93%-25.56%+8.44%-5.63%-32.88%MYNZMainz Biomed-2.06%-1.04%-42.42%+125.09%+24.18%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHOWLWerewolf Therapeutics 2.14Hold$3.75967.46% UpsideLPCNLipocine 2.33Hold$15.00543.78% UpsideMTNBMatinas Biopharma 0.00N/AN/AN/AMYNZMainz Biomed 1.50ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest MTNB, MYNZ, HOWL, and LPCN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2026LPCNLipocine Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/16/2026HOWLWerewolf Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/20/2026HOWLWerewolf Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/6/2026LPCNLipocine HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral3/27/2026LPCNLipocine Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHOWLWerewolf Therapeutics$1.88M9.08N/AN/A$0.51 per share0.69LPCNLipocine$1.98M9.70N/AN/A$2.61 per share0.89MTNBMatinas Biopharma$1.10M3.52N/AN/A$0.75 per share0.81MYNZMainz Biomed$659.94K24.16N/AN/A$2.61 per share0.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHOWLWerewolf Therapeutics-$60.82M-$1.24N/AN/AN/AN/A-208.23%-75.12%8/13/2026 (Estimated)LPCNLipocine-$9.63M-$1.88N/AN/AN/A-571.18%-66.70%-59.39%8/4/2026 (Estimated)MTNBMatinas Biopharma-$10.35M-$3.89N/AN/AN/AN/A-193.02%-124.09%N/AMYNZMainz Biomed-$21.65M-$65.60N/AN/AN/AN/AN/AN/AN/ALatest MTNB, MYNZ, HOWL, and LPCN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2026Q1 2026MTNBMatinas BiopharmaN/A-$0.30N/A-$0.30N/AN/A5/7/2026Q1 2026HOWLWerewolf Therapeutics-$0.32-$0.28+$0.04-$0.28N/AN/A5/7/2026Q1 2026LPCNLipocine-$0.51-$0.54-$0.03-$0.54$0.16 million$0.12 million3/31/2026Q4 2025MTNBMatinas BiopharmaN/A-$0.26N/A-$0.26N/AN/A3/27/2026Q4 2025HOWLWerewolf Therapeutics-$0.34-$0.20+$0.14-$0.20$0.30 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthHOWLWerewolf TherapeuticsN/AN/AN/AN/AN/ALPCNLipocineN/AN/AN/AN/AN/AMTNBMatinas BiopharmaN/AN/AN/AN/AN/AMYNZMainz BiomedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHOWLWerewolf TherapeuticsN/A1.271.27LPCNLipocineN/A9.999.99MTNBMatinas BiopharmaN/A1.321.32MYNZMainz Biomed0.440.520.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHOWLWerewolf Therapeutics64.84%LPCNLipocine9.11%MTNBMatinas Biopharma11.77%MYNZMainz BiomedN/AInsider OwnershipCompanyInsider OwnershipHOWLWerewolf Therapeutics23.60%LPCNLipocine6.35%MTNBMatinas Biopharma4.60%MYNZMainz Biomed18.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHOWLWerewolf Therapeutics4048.60 million37.13 millionOptionableLPCNLipocine108.24 million7.72 millionNo DataMTNBMatinas Biopharma306.41 million6.11 millionN/AMYNZMainz Biomed309.06 million7.41 millionNot OptionableMTNB, MYNZ, HOWL, and LPCN HeadlinesRecent News About These CompaniesMainz BioMed NV: Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors / Name change to Quantum Cyber (QUCY)March 12, 2026 | finanznachrichten.deStrategische Neuausrichtung: Mainz Biomed firmiert in Quantum Cyber um und ernennt neuen ChairmanMarch 11, 2026 | de.investing.comMainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of DirectorsMarch 11, 2026 | globenewswire.comMainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood SamplesFebruary 24, 2026 | markets.businessinsider.comMainz Biomed sichert sich 6 Millionen US-Dollar und richtet Fokus auf BauchspeicheldrüsenkrebsFebruary 17, 2026 | de.investing.comMainz Biomed secures $6 million private placement, shifts focus to US pancreatic cancer programFebruary 17, 2026 | msn.comMainz Biomed Announces 6.0 USD Million Private Placement and Strategic UpdateFebruary 17, 2026 | finance.yahoo.comMainz Biomed nimmt 2,15 Mio. US-Dollar über At-the-Market-Platzierung ein/nFebruary 10, 2026 | de.investing.comMainz Biomed Aktie: Neue Studiendaten vorausFebruary 7, 2026 | stock-world.deSMainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual MeetingJanuary 14, 2026 | globenewswire.comMainz Biomed expects to complete eAArly DETECT 2 study in 2026January 6, 2026 | msn.comMainz Biomed Provides Review of 2025 HighlightsJanuary 5, 2026 | markets.businessinsider.comMainz Biomed Initiates eAArly DETECT 2 Clinical Study to Evaluate Next Generation Colorectal Cancer Test and Advances Pancreatic Cancer Screening ProgramJanuary 5, 2026 | quiverquant.comQMainz Biomed files $150M mixed securities shelfDecember 5, 2025 | msn.comMainz Biomed announces ColoAlert added to portfolio of DoctorBoxDecember 2, 2025 | msn.comDoctorBox Adds Mainz Biomed’s ColoAlert(R) to Its PortfolioDecember 2, 2025 | markets.businessinsider.comMainz BioMed NV: Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South AmericaNovember 18, 2025 | finanznachrichten.deMainz Biomed, OncoVanguard8 agree to bring ColoAlert to South AmericaNovember 18, 2025 | msn.comMainz Biomed Signs Memorandum of Understanding with OncoVanguard8 to Launch ColoAlert® Colorectal Cancer Screening in South AmericaNovember 18, 2025 | quiverquant.comQMainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South AmericaNovember 18, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMTNB, MYNZ, HOWL, and LPCN Company DescriptionsWerewolf Therapeutics NASDAQ:HOWL$0.35 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$0.35 0.00 (-0.09%) As of 06/18/2026 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.Lipocine NASDAQ:LPCN$2.33 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$2.33 0.00 (-0.21%) As of 06/18/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.Matinas Biopharma NYSEAMERICAN:MTNB$0.60 0.00 (0.00%) As of 06/18/2026 04:10 PM EasternMatinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.Mainz Biomed NASDAQ:MYNZ$1.76 -0.14 (-7.37%) As of 06/18/2026Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate American Eagle’s Q1 Beat Leaves Investors With a Bigger Question Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
